Literature DB >> 3132618

[Sphingolipid storage diseases of the central nervous system: bases of biochemical and clinical heterogeneity].

K Sandhoff1, L Quintern.   

Abstract

Lysosomal storage disorders are progredient and often fatal diseases most of which result from a pronounced enzyme deficiency. In the case of sphingolipidoses, usually enzymes of sphingolipid catabolism are missing, or only a few percent of normal activity are detectable. For many sphingolipidoses, damage of the central nervous system is characteristic, but neurological and other symptoms can vary greatly, especially in adult variants. This variability is mainly caused by different allelic mutations of the structural genes, resulting in different levels of residual enzyme activity.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3132618     DOI: 10.1007/bf00405302

Source DB:  PubMed          Journal:  Naturwissenschaften        ISSN: 0028-1042


  56 in total

1.  Adult (chronic) GM2 gangliosidosis. Atypical spinocerebellar degeneration in a Jewish sibship.

Authors:  I Rapin; K Suzuki; K Suzuki; M P Valsamis
Journal:  Arch Neurol       Date:  1976-02

2.  Mapping of the gene coding for the human GM2 activator protein to chromosome 5.

Authors:  J Burg; E Conzelmann; K Sandhoff; E Solomon; D M Swallow
Journal:  Ann Hum Genet       Date:  1985-01       Impact factor: 1.670

3.  Clinical course of GM2 gangliosidoses. A correlative attempt.

Authors:  F J Schulte
Journal:  Neuropediatrics       Date:  1984-09       Impact factor: 1.947

4.  Mutation in GM2-gangliosidosis B1 variant.

Authors:  K Ohno; K Suzuki
Journal:  J Neurochem       Date:  1988-01       Impact factor: 5.372

5.  Enzymatic phosphorylation of lysosomal enzymes in the presence of UDP-N-acetylglucosamine. Absence of the activity in I-cell fibroblasts.

Authors:  A Hasilik; A Waheed; K von Figura
Journal:  Biochem Biophys Res Commun       Date:  1981-02-12       Impact factor: 3.575

6.  Model for the interaction of membrane-bound substrates and enzymes. Hydrolysis of ganglioside GD1a by sialidase of neuronal membranes isolated from calf brain.

Authors:  G Scheel; E Acevedo; E Conzelmann; H Nehrkorn; K Sandhoff
Journal:  Eur J Biochem       Date:  1982-10

7.  Molecular cloning of the sphingolipid activator protein-1 (SAP-1), the sulfatide sulfatase activator.

Authors:  N Dewji; D Wenger; S Fujibayashi; M Donoviel; F Esch; F Hill; J S O'Brien
Journal:  Biochem Biophys Res Commun       Date:  1986-01-29       Impact factor: 3.575

8.  Juvenile spinal muscular atrophy: a new hexosaminidase deficiency phenotype.

Authors:  W G Johnson; H J Wigger; H R Karp; L M Glaubiger; L P Rowland
Journal:  Ann Neurol       Date:  1982-01       Impact factor: 10.422

9.  Incorporation and metabolism of ganglioside GM2 in skin fibroblasts from normal and GM2 gangliosidosis subjects.

Authors:  S Sonderfeld; E Conzelmann; G Schwarzmann; J Burg; U Hinrichs; K Sandhoff
Journal:  Eur J Biochem       Date:  1985-06-03

10.  Chronic GM2 gangliosidosis masquerading as atypical Friedreich ataxia: clinical, morphologic, and biochemical studies of nine cases.

Authors:  J P Willner; G A Grabowski; R E Gordon; A N Bender; R J Desnick
Journal:  Neurology       Date:  1981-07       Impact factor: 9.910

View more
  2 in total

1.  [Glycolipids of the cell surface--biochemistry of their decomposition].

Authors:  K Sandhoff; T Kolter
Journal:  Naturwissenschaften       Date:  1995-09

2.  Membrane lipids and their degradation compounds control GM2 catabolism at intralysosomal luminal vesicles.

Authors:  Susi Anheuser; Bernadette Breiden; Konrad Sandhoff
Journal:  J Lipid Res       Date:  2019-04-15       Impact factor: 5.922

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.